NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Rating of “Moderate Buy” by Analysts

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $48.60.

A number of research firms have weighed in on NAMS. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Truist Financial assumed coverage on NewAmsterdam Pharma in a research note on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target for the company.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $33.24 on Monday. The firm has a market capitalization of $3.89 billion, a price-to-earnings ratio of -18.57 and a beta of 0.07. NewAmsterdam Pharma has a one year low of $17.97 and a one year high of $42.21. The business has a fifty day moving average price of $32.80 and a 200-day moving average price of $33.12.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The company had revenue of $3.04 million during the quarter. On average, equities research analysts expect that NewAmsterdam Pharma will post -1.78 earnings per share for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $30.20, for a total value of $1,208,000.00. Following the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $735,460.60. The trade was a 62.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.74% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NAMS. Capital World Investors lifted its holdings in shares of NewAmsterdam Pharma by 17.1% in the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares in the last quarter. Duquesne Family Office LLC lifted its holdings in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after buying an additional 1,091,525 shares in the last quarter. Castle Hook Partners LP purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $38,062,000. Adage Capital Partners GP L.L.C. lifted its stake in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in NewAmsterdam Pharma by 96.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock worth $60,536,000 after purchasing an additional 845,110 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.